The standardized extract of Ginkgo biloba in this preparation is commonly used to help manage symptoms across several domains associated with age-related or microcirculatory issues. Within this context, the extract is used for the management of specific, distressing symptoms in adults.

This medicine is commonly used to help with symptoms related to age-associated cognitive impairment, the early stages of mild-to-moderate dementia, peripheral arterial occlusive disease (intermittent claudication), and balance disorders like vertigo and unsteadiness.

It is applied when symptom clusters involve diminished concentration, impaired memory capacity, and discomfort in the legs upon walking that interfere with daily functioning. The benefit is that it supports the easing of the overall symptom burden and helps general well-being. It is relevant when supportive symptom management is appropriate and symptoms create noticeable functional strain.

---

Quick Fact: Symptom Support Domains

By addressing these issues, the treatment contributes to assisting with maintaining a sense of functional stability and helps support overall day-to-day comfort and mobility during symptomatic periods.

Regulatory References

1. European Medicines Agency (EMA) review on Ginkgo folium

The official regulatory profile for Мемоплант (standardized Ginkgo biloba extract) strictly defines the eligible and excluded populations. Use is established for adults and older people. The product is generally not recommended for use in children and adolescents under 18 years of age due to insufficient data to confirm safety and efficacy.

---

Eligibility Scope

Classification	Population/Status
Contraindicated Use	Pregnancy; Hypersensitivity to Ginkgo preparations or tablet excipients; Patients with congenital galactosemia, lactase deficiency, or glucose-galactose malabsorption.
Not Recommended Status	Children and adolescents under 18 years of age; Patients who are breastfeeding/lactating.

---

Eligibility-Related Restrictions

Conditional use is required for individuals with specific pre-existing conditions. Patients with a known bleeding disorder or those taking anti-clotting medication must proceed with caution due to the drug’s potential anti-platelet activity. Similarly, patients with epilepsy or a history of seizure disorders are advised to use the product conditionally, as the possibility of further seizure onset cannot be excluded. Discontinuation is required at least two weeks before any scheduled surgery.

Interactions with other medicines and products

Official regulatory documentation outlines several interaction patterns for standardized Ginkgo biloba extract based on both pharmacokinetic and pharmacodynamic effects.

Pharmacokinetic and Pharmacodynamic Interactions

The extract has the documented potential to affect the clearance of co-administered medicines through enzyme and transporter induction. It can induce the Cytochrome P450 3A4 (CYP3A4) enzyme and the P-glycoprotein (P-gp) efflux transporter, which may result in enhanced metabolism and reduced systemic exposure for sensitive substrate medicines.

A primary pharmacodynamic concern is the risk of additive bleeding when co-administered with agents that affect the coagulation system. This interaction is formally documented for co-use with oral anticoagulants (e.g., Warfarin) and antiplatelet agents (e.g., Acetylsalicylic acid and NSAIDs).

Interaction-Related Restrictions

Category	Officially Documented Restriction
Specific Medicine	Co-administration with Efavirenz is formally restricted in regulatory labeling due to the risk of reduced efavirenz plasma concentrations and subsequent potential for therapeutic failure.
Herbal Products	Cautions are documented for co-use with other herbal products or supplements that are known to increase bleeding risk, due to potential additive pharmacodynamic effects.

No mandatory timing rules concerning the separation of administration have been explicitly stated in regulatory documents.

The mechanism of action for Мемоплант (standardized Ginkgo biloba extract) is a multi-target approach that modulates vascular dynamics, cellular integrity, and chemical signaling.

Optimization of Cerebral Microcirculation

The Terpene Lactones (Ginkgolides) act as non-competitive antagonists of the Platelet-Activating Factor (PAF) receptor, which inhibits platelet aggregation and lowers blood viscosity. This cascade leads to enhanced cerebral perfusion and a more stable supply of oxygen and glucose to neuronal tissue.

Cellular Defense Against Oxidative Stress

The Ginkgo Flavone Glycosides function as free radical scavengers and inhibit lipid peroxidation, a process that degrades neuronal membranes. This mechanism stabilizes the mitochondrial function and exerts a neuroprotective effect against metabolic and oxidative damage.

Modulation of Neurochemical Communication

Components of the extract mildly inhibit the reuptake transporters for certain monoamines (such as Norepinephrine and Dopamine). This action leads to increased and sustained concentrations of these neurotransmitters in the synapse, which modulates synaptic signaling and influences communication dynamics within the central nervous system.

The administration of Мемоплант is governed by established use guidelines for the standardized Ginkgo biloba leaf dry extract, ensuring consistent dosing and appropriate duration for the supportive treatment intended for adults and the elderly. The medicine is consistently approved for the oral use route, primarily in the form of film-coated tablets or an oral liquid preparation.

---

Administration Scope

Parameter	Instruction
Route of administration:	Oral use (ingestion).
Dosing schedule:	The standard daily dose ranges from 120 mg to 240 mg of the standardized dry extract. The total amount administered daily should not typically exceed 240 mg.
Timing in relation to meals (if applicable):	Tablets should generally be taken with or after meals (post-prandial administration) and swallowed whole with water.
Age-group administration rules:	The designated population for use is Adults and the Elderly. The use of this preparation is not recommended in children and adolescents under 18 years of age.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type:	Oral
Frequency pattern:	Daily use, typically administered in divided doses (e.g., two or three times per day), or as a single 240 mg dose.
Basis of use:	Well-established use of Ginkgo biloba extract.
Use-context constraints:	A minimum continuous course of at least 8 to 12 weeks is required before assessing its supportive effect.

---

Resulting Procedural Structure

Official Step Sequence:

• The appropriate total daily dose of the standardized extract is identified based on the product’s label.
• This total daily dose is administered in the specified number of divided doses.
• Each dose is taken orally, with liquid, and in the context of a meal.

Connection to the Overall Use Protocol

This protocol mandates continuous, daily oral administration of a standardized dose, often split into multiple administrations, for a period lasting several weeks or months. This defined method and course duration are crucial elements of the guidelines for its proper use.

Research Evidence / Overview of Studies for Мемоплант

Evidence for Age-Associated Cognitive Impairment and Memory Support

Research for this standardized extract primarily involves Randomized Controlled Trials (RCTs) and meta-analyses, which are study types used to explore changes in symptoms related to diminished concentration and mild-to-moderate dementia in older adults. Studies explored differences in cognitive assessment scores between the tested group and the control group, and these findings contribute to the broader evidence landscape. However, long-term effects are not fully established; follow-up durations were often limited to less than six months, and results from trials tracked over a year or more have been mixed.

Evidence for Managing Peripheral Circulation and Balance

The extract was studied for use in individuals with stable peripheral arterial occlusive disease (PAOD), a condition where symptoms may vary in intensity during activity. Research examined outcomes reflecting daily functioning, such as the maximum distance walked before pain onset. Some trials data show patterns related to individuals describing differences in their walking capability. Furthermore, the extract was evaluated in research exploring short-term changes associated with vertigo and dizziness, where some participants reported changes in the frequency or intensity of their symptoms.

Evidence Gaps and Areas of Scientific Uncertainty

The research landscape contains several gaps where data are still emerging. For chronic tinnitus, the findings were mixed, and evidence quality varies across studies. Overall, the certainty remains low or moderate across some indications due to modest sample sizes or heterogeneity (variability) in results. The results apply only to the populations studied, and data for certain groups, such as younger adults seeking cognitive support, remains insufficient.

Common questions about Мемоплант (FAQ)

Q: Is Мемоплант considered a supplement or a prescription medicine?

A: Official regulatory sources classify Мемоплант as an officially registered herbal medicinal product, which is a type of phytomedicine. This status means it has been reviewed by authorities based on defined quality and is distinguished from general food supplements.

Q: Are there different strengths or dosages of Мемоплант?

A: Official dosing guidance for the extract specifies a total daily dose ranging from 120 mg to 240 mg. This range may be covered by different marketed tablet strengths, as detailed in the patient information.

Q: What is the longest period people typically use Мемоплант for?

A: The medicine is used to relieve symptoms, and a continuous course is required to assess its supportive effect. Official guidance states that if symptoms worsen or persist for more than four weeks, it is advised to consult a doctor or a qualified healthcare professional.

Q: Is Мемоплант the same as other Ginkgo biloba products?

A: No. Мемоплант contains a standardized dry extract of Ginkgo biloba leaves, meaning the key active components are precisely measured and consistent. This standardized composition is a requirement for its status as a recognized herbal medicinal product.

Q: Can Мемоплант be taken alongside vitamins or minerals?

A: Regulatory texts caution against taking Мемоплант alongside other herbal products or supplements that are known to increase the risk of bleeding. Patients who are taking specific vitamins or minerals should consult a doctor or pharmacist regarding potential interactions.

Q: Is it possible to take Мемоплант if I have stomach issues?

A: Gastrointestinal disturbances, such as nausea or abdominal pain, are listed in official documents as common side effects of the medicine. Consultation with a doctor or pharmacist before use is advised if there are pre-existing stomach issues.

Q: Is the effect of Мемоплант permanent or only while using it?

A: The medicine is intended for supportive treatment to relieve symptoms, and evidence indicates that a minimum continuous course is required to see the intended effect. Official research summaries state that long-term effects beyond the typical study duration are not fully established.

Q: Is there a generic version of Мемоплант available?

A: Мемоплант is a specific brand name. However, similar registered herbal medicinal products containing the same standardized Ginkgo biloba dry extract may be available on the market.

Q: Is there official guidance on discontinuing Мемоплант?

A: Official safety guidance formally advises that the medicine be discontinued three to four days prior to any scheduled surgical procedures. For other situations, consultation with a doctor or pharmacist is recommended.

Q: Can I use Мемоплант if I am sensitive to certain dyes, additives, or common allergens?

A: Use is contraindicated if an individual has hypersensitivity to the extract or to any of the excipients (non-active ingredients) in the tablet. Regulatory warnings note that some products contain components like soya polysaccharide, which may affect individuals with soya or peanut allergies.

Q: What happens if I forget to take a dose of Мемоплант?

A: Official patient information advises that if a dose is forgotten, a double dose should not be taken to make up for the missed one. The next dose should be taken at the usual time.

Q: Does alcohol change the way Мемоплант works?

A: While the tablet form does not usually carry a specific alcohol warning, the oral liquid preparation of the standardized extract contains ethanol. This is a consideration for patients who are taking other medications that may interact with alcohol or affect the central nervous system.

Q: Is Мемоплант safe for individuals who have diabetes?

A: Regulatory sources advise that patients with diabetes should use the product with caution. This is because the extract might interfere with blood sugar management, and close monitoring of blood sugar levels is generally advised for patients with diabetes.

Q: What happens if a child accidentally takes Мемоплант?

A: If a child accidentally takes too much of the product, official safety guidance advises immediate medical attention or contact with a poison control center. The product is not recommended for use in children and adolescents under 18 years of age.

Q: Does Мемоплант have warnings about driving or operating machinery?

A: Regulatory documentation states that no specific studies have been performed on the effects of this extract on the ability to drive and use heavy machinery. A cautious approach is advised until an individual knows how the product affects them.

Q: Are there documented cases of overdose with Мемоплант?

A: In the event of an overdose or if more than the recommended amount is taken, the regulatory information advises that immediate medical advice should be sought or emergency services/a poison control center contacted.

Q: Can Мемоплант be used by individuals who are vegan or vegetarian?

A: The product's suitability for vegans or vegetarians depends entirely on the non-active ingredients (excipients) used in the film coating and tablet core. The product's Patient Information Leaflet should be consulted for the full list of excipients.

Q: What should I do if I experience an unexpected effect while taking Мемоплант?

A: If any side effects are experienced, including any unexpected effects not listed in the patient information leaflet, official advice recommends reporting them to a doctor, pharmacist, or nurse.

How to Store and Dispose of Memoplant?

The storage and disposal of Memoplant (standardized Ginkgo biloba extract tablets) are strictly governed by regulatory requirements to ensure product integrity and environmental safety.

---

Storage Requirements

• Temperature: Do not store above 25 C.
• Protection: Keep the medicine in the original package to shield the film-coated tablets from moisture and light.
• Child Safety: This medicine must be stored out of the sight and reach of children.

Disposal Instructions

• Environmental Restriction: Do not throw away any medicines via wastewater or household waste.
• Waste Handling: Dispose of unused or expired product in accordance with local pharmaceutical waste requirements (e.g., return to a pharmacist).